A
BIO icon

AustralianSuper’s Bio-Rad Laboratories Class A BIO Stock Holding History

AustralianSuper’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-254,901
Closed -$122M – 268
2023
Q1 		$122M Sell
254,901
-68,755
-21% -$32.2M 0.74% 35
2022
Q4 		$137M Sell
323,656
-69,338
-18% -$28M 0.91% 31
2022
Q3 		$164K Buy
392,994
+5,427
+1% +$2.71M 1.17% 28
2022
Q2 		$192K Buy
+387,567
New +$202M 1.18% 29

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

AustralianSuper's BIO Position: Q2 2023 in Review

AustralianSuper sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 254,901 shares — an estimated $122M sold.

AustralianSuper first reported a position in BIO in Q2 2022 and held it in 4 quarters. The position peaked at $137M in Q4 2022. 468 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • AustralianSuper reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • AustralianSuper sold 254,901 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $122M.
  • AustralianSuper first reported a position in Bio-Rad Laboratories Class A in Q2 2022 and held it in 4 quarters.
  • AustralianSuper's Bio-Rad Laboratories Class A position peaked at $137M in Q4 2022.
  • 468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on AustralianSuper's 13F filing for Q2 2023, filed 28 Jul 2023.